CEP70

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, CEP70 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CEP70 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CEP70 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CEP70 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC and LSCC are the cancer types where CEP70 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
PDACOSMedianAll0.8550.224.00630view →
LSCCDFSMedianAll1.0000.875.01714view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CEP70–PDAC (OS)

Kaplan–Meier survival curve for CEP70 mass-spec protein-high vs -low samples in PDAC.

Open the PDAC breakdown →

Exploration